Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

RCT (n=353) found longer disease-free survival with adjuvant nivolumab than placebo in intention-to-treat population (20.8 vs.10.8 months; 74.9 vs. 60.3% alive & disease-free at 6 months;HR 0.70; 98.22% CI, 0.55 to 0.90; p<0.001) and among patients with PD-L1 expression of ≥1%.

Source:

New England Journal of Medicine